Gilead Sciences GILD
NASDAQ GILD
$145.69 -0.95 (-0.65%)
As of: Sep 9, 2026 · 3:59 PM EDT

Gilead Sciences (GILD) Finished Goods (2009 - 2015)

Gilead Sciences' (GILD) quarterly Finished Goods came in at $852.0 million in Q4 2015, up 82.83% on a YoY basis from $466.0 million in Q4 2014, and up 82.83% quarter-over-quarter from $466.0 million in Q4 2014.

Analysis

Gilead Sciences (GILD) Finished Goods (2009 - 2015) Analysis & Trends

Gilead Sciences (GILD) has reported Finished Goods for 7 consecutive years, with $852.0 million the latest figure, recorded in Q4 2015.

  • For the quarter ending Q4 2015, Finished Goods rose 82.83% year-over-year to $852.0 million; the trailing twelve-month figure through Dec 2015 stood at $852.0 million (up 82.83% YoY), and the FY2015 full-year result was $852.0 million, up 82.83% from the prior year.
  • Finished Goods grew to $852.0 million in Q4 2015 per GILD's latest filing, from $466.0 million in the prior quarter.
  • Across five years, Finished Goods topped out at $852.0 million in Q4 2015 and bottomed at $225.9 million in Q4 2011.
  • Historically, Finished Goods has averaged $487.3 million across 5 years, with a median of $466.0 million in 2014.
  • The sharpest annual moves came in 2011 and 2012: Finished Goods slumped 33.79% in 2011, then surged 147.9% in 2012.
  • Over 5 years, Finished Goods stood at $225.9 million in 2011, then soared by 147.9% to $559.9 million in 2012, then gained by 5.99% to $593.4 million in 2013, then slipped by 21.47% to $466.0 million in 2014, then surged by 82.83% to $852.0 million in 2015.
  • According to Business Quant data, Finished Goods over the past three periods registered $852.0 million, $466.0 million, and $560.0 million for Q4 2015, Q4 2014, and Q2 2014 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2015 852.00 Mn
Dec 31, 2014 466.00 Mn
Jun 30, 2014 559.98 Mn
Dec 31, 2013 593.44 Mn
Dec 31, 2012 559.91 Mn
Dec 31, 2011 225.86 Mn
Sep 30, 2011 295.79 Mn
Jun 30, 2011 384.72 Mn
Mar 31, 2011 448.43 Mn
Dec 31, 2010 341.14 Mn
Sep 30, 2010 439.32 Mn
Dec 31, 2009 326.15 Mn